Clinical Trial Update: Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating an IL-15/IL-21 armored GPC3-targeted CAR-T cell therapy for pediatric solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liposarcoma
• Malignant Rhabdoid Tumor
• Rhabdomyosarcoma
• Wilms Tumor
• Yolk Sac Tumor

Drugs mentioned

• IL-15/IL-21 armored GPC3-specific CAR-T cell therapy

Snippet

Sponsor: Baylor College of Medicine | Conditions: Liver Cancer, Rhabdomyosarcoma | Phase 1 | Status: RECRUITING